Literature DB >> 448527

The high risk of chronic liver disease in multitransfused juvenile hemophiliac patients.

J A Spero, J H Lewis, S E Fisher, U Hasiba, D H Van Thiel.   

Abstract

Eighty-seven asymptomatic children with either hemophilia A or B were treated before they were 21 years of age. Seventy-two received factor concentrates and 15 cryoprecipitate or fresh-frozen plasma only. Thirty-two of the 72 in the former group have persistently elevated alanine aminotransferase values compared to one of 15 in the latter group. In a subset of children treated with factor concentrates before five years of age, four of seven are chronically HBsAg positive. Liver biopsies were performed in 13 of the 32 asymptomatic patients with abnormal ALT values in the fraction group. It is recommended that until further data become available, children with mild hemophilia and all less than 5 years of age should receive only cryo or FFP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448527     DOI: 10.1016/s0022-3476(79)80205-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

2.  Hepatitis B virus infection in multitransfused haemophiliacs.

Authors:  G Nebbia; G A Moroni; L Simoni; M Belli; V Carnelli
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

3.  Coagulation factor therapy for hemophilia: relation to hepatitis B and to liver function.

Authors:  R T Card; M Dusevic; B E Lukie
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.